Personalized antisense oligonucleotide therapy (nL18576)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Personalized antisense oligonucleotide therapy (nL18576), covering 2026-02-20 to 2026-02-20. Get the full timeline:
Most recent: Clinical Trial Update: Personalized Antisense Oligonucleotide Therapy for A Single Patient With CHCHD10 ALS (nL18576) [Phase 1, Phase 2]